News Releases
- February 16, 2021Annovis Bio to Present at the BIO CEO & Investor Digital Conference
- February 4, 2021Annovis Bio Receives European Patent for Method of Treating Acute Nerve and Brain Insults
- February 2, 2021Annovis Bio's Lead Candidate ANVS401 Improves Cognitive and Functional Outcomes in Stroke Mice Study
- January 5, 2021Annovis Bio to Present at H.C. Wainwright BioConnect 2021 Conference
- December 17, 2020Annovis Bio Interview to Air on Bloomberg International on the RedChip Money Report
- December 15, 2020Annovis Bio Showcases its Unique Approach to Alzheimer’s at the New York Academy of Sciences
- December 7, 2020Annovis Bio to Present at Benzinga Global Small Cap Conference on December 8, 2020
- December 3, 2020Annovis Bio to Present at the New York Academy of Sciences’ Alzheimer's Disease Therapeutics: Alternatives to Amyloid 2020 Virtual Conference
- November 16, 2020Annovis Bio to Participate in A.G.P.'s Virtual Healthcare Symposium
- November 12, 2020Annovis Bio Reports Positive Results from Final Phase of $1.9M NIH Funded Chronic Toxicology Study for its Lead Compound for the Treatment of Alzheimer’s and Parkinson’s Diseases
- ,
Media Coverage
Events & Presentations
-
Annovis R&D Day Webcast View Webcast
-
Annovis Corporate Presentation - February 2024
-
AD-PD Conference - March 2022
Filings
Filings
Description
Date Filed
Available Formats
E-mail Alerts
Back to Top